NMPA approves IND for a Ph 1b/2 Clinical Trial of PD-L1-Targeting ADC HLX43
“Shanghai Henlius Biotech, Inc. announced that the investigational new drug (IND) application for a phase 1b/2 clinical trial of HLX43 for Injection, the antibody-drug conjugate (ADC) product that developed by the company based on the collaboration with MediLink Therapeutics, has been approved by the China National Medical Products Administration (NMPA), for monotherapy or combination therapy to treat patients with advanced/metastatic solid tumours. In November 2023, a phase 1 clinical trial of HLX43 has completed dosing its first subject, making it the first PD-L1-targeting ADC in China to enter a clinical trial. At present, no PD-L1 targeting ADC has been approved for marketing globally.”
Share:
More News
“T-cell engagers targeting CD3 have successfully exploited the first signal in T-cell receptor signaling to treat liquid tumors, significantly expanding the treatment options for these cancers. However, solid tumors represent a much greater unmet clinical need that has yet to benefit from advances in immune-engaging bispecific antibodies,” said Nathan Trinklein,
“We are pleased to advance the clinical development of ADRX-0706 into the Phase 1b dose expansion cohorts,” said Hui Li, Ph.D., Founder and Chief Executive Officer of Adcentrx. “Encouraging findings from our Phase 1a trial demonstrate the best-in-class potential for ADRX-0706, with differentiated safety and pharmacokinetic properties, including a much
“The BOND-003 monotherapy data underscores our novel investigational oncolytic immunotherapy’s unique product profile, including its dual mechanism of action, which we believe differentiates it from current and investigational NMIBC treatments,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “Based upon the latest data, we are confident that cretostimogene
“Receiving a second FDA Fast Track Designation for LP-184 reinforces the significant potential of this drug candidate to address critical unmet needs in aggressive cancers, especially those like TNBC where patients have limited therapeutics options,” stated Panna Sharma, President and CEO of Lantern Pharma. “Recent data presented at the Immuno-Oncology
